<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="c23688c3-a0ff-40bd-aa0c-9ebee4f69119"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PLENVU safely and effectively. See full prescribing information for PLENVU.<br/>PLENVU<sup>®</sup> (polyethylene glycol 3350, sodium ascorbate, sodium sulfate,<br/>ascorbic acid, sodium chloride and potassium chloride for oral solution)<br/>Initial U.S. Approval: 2006</title>
   <effectiveTime value="20230901"/>
   <setId root="79f930fa-5674-4f30-8ae8-9448d6243797"/>
   <versionNumber value="12"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="793108036" root="1.3.6.1.4.1.519.1"/>
            <name>Salix Pharmaceuticals, Inc</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="239828197" root="1.3.6.1.4.1.519.1"/>
                        <name>Norgine Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65649-400" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="b1f22d29-cb75-48ca-9f8c-f5b7ba64fdce"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230901"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="65649-400" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Plenvu</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="65649-400-02" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="65649-400-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator unit="1" value="115.96"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Dose 1</name>
                              <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="100"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>POLYETHYLENE GLYCOL 3350</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="9"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="0YPR65R21J" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM SULFATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="36KCS0R750" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>SODIUM SULFATE ANHYDROUS</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="2"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>CHLORIDE ION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>POTASSIUM CATION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SUCRALOSE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CITRIC ACID MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="I629I3NR86" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MANGO</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="115.96"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209381" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="46.26"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Dose 2 Pouch A</name>
                              <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, POTASSIUM CHLORIDE</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="40"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>POLYETHYLENE GLYCOL 3350</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="3.2"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>CHLORIDE ION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="1.2"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>POTASSIUM CATION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="Z0H242BBR1" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ASPARTAME</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="46.26"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209381" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator unit="1" value="55.65"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Dose 2 Pouch B</name>
                              <formCode code="C42973" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POWDER, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>SODIUM ASCORBATE, ASCORBIC ACID</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="g" value="48.11"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="S033EH8359" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM ASCORBATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ASCORBIC ACID</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="g" value="7.54"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ASCORBIC ACID</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="PQ6CK8PD0R" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ASCORBIC ACID</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="55.65"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic classCode="OBS">
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CE"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA209381" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20180504"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA209381" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180504"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_1109d1f6-15da-4243-96c0-c765f705941e">
               <id root="9ebeb4d0-8c08-4da9-a892-d40c8249a9a6"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dosage and Administration (<linkHtml href="#_Ref">2.1</linkHtml>)                                                              9/2023</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_fd7ca134-7cbc-4845-a9bf-da69ffaaca84">
               <id root="8af2a7d2-2994-4200-beb8-d255acc34573"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE </title>
               <text>
                  <paragraph>PLENVU<sup>®</sup> is indicated for cleansing of the colon in preparation for colonoscopy in adults.</paragraph>
               </text>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>PLENVU is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults. (<linkHtml href="#ID_fd7ca134-7cbc-4845-a9bf-da69ffaaca84">1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_f792f650-a8c6-45dc-b586-324bf00dff6e">
               <id root="0e43f447-eec6-42a0-b609-58d7408bd03b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION </title>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Preparation and Administration:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Two doses of PLENVU are required for a complete preparation for colonoscopy, using a “Two-Day” or “One-Day” dosage regimen. (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Reconstitute PLENVU in water prior to ingestion. (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Consume additional clear liquids after each dose of PLENVU in both dosing regimens. (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>, <linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Administer oral medications at least 1 hour before starting each dose of PLENVU. (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>, <linkHtml href="#ID_0cc1ef6e-42ba-4dcf-9cfa-fc515bf1533a">7.2</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage Regimens:</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Two-Day Split Dosage</content>: Dose 1 the evening before the colonoscopy (approximately 4 pm to 8 pm) and Dose 2 the next morning (approximately12 hours after the start of Dose 1). (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>, <linkHtml href="#ID_953d2662-091f-4f7e-813f-ab1f21eba347">2.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">One-Day Morning Dosage</content>: Dose 1 the morning of the colonoscopy (approximately 3 am to 7 am) and Dose 2 a minimum of 2 hours after the start of Dose 1. (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>, <linkHtml href="#ID_0d7d84ad-f359-4dbe-8a16-c952b5933fc5">2.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>For complete information on dosing, preparation and administration, see full prescribing information. (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>, <linkHtml href="#ID_953d2662-091f-4f7e-813f-ab1f21eba347">2.2</linkHtml>, <linkHtml href="#ID_0d7d84ad-f359-4dbe-8a16-c952b5933fc5">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_8926f07b-fec6-4280-a270-d3ebc7a06085">
                     <id root="158fa66c-180c-4cc2-aba4-e4d7254dbe3e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Preparation and Administration Instructions </title>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Correct fluid and electrolyte abnormalities before treatment with PLENVU <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>)]</content>.</item>
                           <item>
                              <caption>•</caption>Two doses of PLENVU are required for a complete preparation for colonoscopy. The time interval between the two doses depends on the regimen prescribed and the planned timing of the colonoscopy procedure <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_953d2662-091f-4f7e-813f-ab1f21eba347">2.2</linkHtml>, <linkHtml href="#ID_0d7d84ad-f359-4dbe-8a16-c952b5933fc5">2.3</linkHtml>)]</content>.</item>
                           <item>
                              <caption>•</caption>The recommended “Two-Day Split Dosage” method consists of two separate doses: the first dose is taken the evening before the colonoscopy and the second dose is taken the next day, the morning of the day of the colonoscopy <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_953d2662-091f-4f7e-813f-ab1f21eba347">2.2</linkHtml>)].</content>
                           </item>
                           <item>
                              <caption>•</caption>The recommended “One-Day Morning Dosage” method consists of two separate doses: both doses are taken in the morning of the day of the colonoscopy, with a minimum of 2 hours between the start of the first dose and the start of the second dose <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_0d7d84ad-f359-4dbe-8a16-c952b5933fc5">2.3</linkHtml>)].</content>
                           </item>
                           <item>
                              <caption>•</caption>Reconstitute each pouch of PLENVU in the mixing container with water prior to ingestion. It may take 2 to 3 minutes for complete dissolution. Do not reconstitute with other liquids and/or add starch-based thickeners to the mixing container <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#_Ref">5.7</linkHtml>)].</content>
                           </item>
                           <item>
                              <caption>•</caption>Consume additional clear liquids (including water) in both dosing regimens <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_953d2662-091f-4f7e-813f-ab1f21eba347">2.2</linkHtml>, <linkHtml href="#ID_0d7d84ad-f359-4dbe-8a16-c952b5933fc5">2.3</linkHtml>), Warnings and Precautions (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>)]</content>.</item>
                           <item>
                              <caption>•</caption>Consume only clear liquids (no solid food) from the start of PLENVU treatment until after the colonoscopy.</item>
                           <item>
                              <caption>•</caption>Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material.</item>
                           <item>
                              <caption>•</caption>Do not take other laxatives while taking PLENVU.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="xmChange">Administer oral medications at least 1 hour before starting each dose of PLENVU [see Drug Interactions (</content>
                              <linkHtml href="#_Ref">7.2</linkHtml>
                              <content styleCode="xmChange">)].</content>
                           </item>
                           <item>
                              <caption>•</caption>Ensure completion of Dose 2, including all additional liquids, at least 2 hours before the colonoscopy.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_953d2662-091f-4f7e-813f-ab1f21eba347">
                     <id root="d5a34595-4d1d-4db2-8b7a-0c3d0325285c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Two-Day Split Dosage Regimen</title>
                     <text>
                        <paragraph>The recommended Two-Day Split Dosage regimen commences in the evening of the day before the colonoscopy.</paragraph>
                        <paragraph>Instruct adult patients that on the day before the clinical procedure, they can consume a light breakfast followed by a light lunch, which must be completed at least 3 hours prior to the start of the first PLENVU dose.</paragraph>
                        <paragraph>Instruct patients to take two separate doses in conjunction with clear liquids as follows:</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dose 1 – In the evening before the colonoscopy, between approximately 4 pm and 8 pm:</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Empty the contents of Dose 1 into the mixing container that comes with PLENVU.</item>
                           <item>
                              <caption>2.</caption>Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the       PLENVU solution.</item>
                           <item>
                              <caption>3.</caption>Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).</item>
                           <item>
                              <caption>4.</caption>Drink over the next 30 minutes. Be sure to drink all of the solution. </item>
                           <item>
                              <caption>5.</caption>Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.</item>
                           <item>
                              <caption>6.</caption>Consume additional clear liquids during the evening.</item>
                           <item>
                              <caption>7.</caption>If severe bloating, abdominal distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Dose 2 – The next morning, on the day of the colonoscopy, approximately 12 hours after the start of Dose 1 (between<content styleCode="italics"> </content>approximately 4 am and 8 am):</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Empty the contents of Dose 2 Pouch A and Dose 2 Pouch B into the mixing container that comes with PLENVU.</item>
                           <item>
                              <caption>2.</caption>Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.</item>
                           <item>
                              <caption>3.</caption>Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).  Drink over the next 30 minutes. Be sure to drink all of the solution.</item>
                           <item>
                              <caption>4.</caption>Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.</item>
                           <item>
                              <caption>5.</caption>Consume additional water or clear liquids up to 2 hours before the colonoscopy or as prescribed by your doctor. <content styleCode="italics">
                                 <content styleCode="underline">Then stop drinking liquids until after the colonoscopy.</content>
                              </content>
                           </item>
                        </list>
                        <paragraph>Stop drinking PLENVU temporarily or drink each portion at longer intervals if severe bloating, abdominal discomfort or distention occurs, until these symptoms resolve.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0d7d84ad-f359-4dbe-8a16-c952b5933fc5">
                     <id root="d31d2762-a835-43c5-8a41-8b9769beaefb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended One-Day Morning Dosage Regimen</title>
                     <text>
                        <paragraph>The recommended One-Day Morning Dosage regimen commences in the morning of the day of the colonoscopy.</paragraph>
                        <paragraph>Instruct adult patients that on the day before the clinical procedure, they can consume a light breakfast followed by a light lunch, and clear broth soup and/or plain yogurt for dinner, which should be completed by approximately 8 pm.</paragraph>
                        <paragraph>Instruct patients to take two separate doses in conjunction with clear liquids as follows:</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dose 1 – On the day of the colonoscopy, between approximately 3 am and 7 am:</content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Empty the contents of Dose 1 into the mixing container that comes with PLENVU.</item>
                           <item>
                              <caption>2.</caption>Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.</item>
                           <item>
                              <caption>3.</caption>Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes).</item>
                           <item>
                              <caption>4.</caption>Drink over the next 30 minutes. Be sure to drink all of the solution.</item>
                           <item>
                              <caption>5.</caption>Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes.</item>
                           <item>
                              <caption>6.</caption>If severe bloating, abdominal distention, or abdominal pain occurs following the first dose, delay the second dose until the symptoms resolve.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Dose 2 – On the day of the colonoscopy, a minimum of 2 hours after the start of Dose 1:  </content>
                        </paragraph>
                        <list listType="ordered">
                           <item>
                              <caption>1.</caption>Empty the contents of Dose 2 Pouch A and Dose 2 Pouch B into the mixing container that comes with PLENVU.</item>
                           <item>
                              <caption>2.</caption>Add water to the fill line on the mixing container (at least 16 fluid ounces). Do not add other ingredients to the PLENVU solution.</item>
                           <item>
                              <caption>3.</caption>Thoroughly mix with a spoon or shake with lid on securely until completely dissolved (which may take 2 to 3 minutes). Drink over the next 30 minutes. Be sure to drink all of the solution.</item>
                           <item>
                              <caption>4.</caption>Refill the mixing container to the fill line (at least 16 fluid ounces) with clear liquids and drink over the next 30 minutes. </item>
                           <item>
                              <caption>5.</caption>Consume additional water or clear liquids up to 2 hours before the colonoscopy or as prescribed by your doctor. <content styleCode="underline">
                                 <content styleCode="italics">Then</content> <content styleCode="italics">stop drinking liquids until after the colonoscopy.</content>
                              </content>
                           </item>
                        </list>
                        <paragraph>Stop drinking PLENVU temporarily or drink each portion at longer intervals if severe bloating, abdominal discomfort or distention occurs, until these symptoms resolve.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Storage:</content>
                           <br/>After reconstitution, keep PLENVU solution at room temperature, between 68°F to 77°F (20°C to 25°C) [see USP Controlled Room Temperature]. The solution may also be stored in a refrigerator. Use within 24 hours after it is mixed in water.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9cf9570b-3be8-4a00-82fd-0f1630c8e1cb">
               <id root="f73c2dea-05d5-4355-97c3-a8b803988806"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS </title>
               <text>
                  <paragraph>PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is supplied as a white to yellow powder for reconstitution.</paragraph>
                  <paragraph>First dose: one pouch labeled Dose 1; Second dose: two pouches labeled Dose 2 Pouch A and Dose 2 Pouch B. </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Dose 1 contains 100 grams of polyethylene glycol (PEG) 3350, 9 grams of sodium sulfate, 2 grams of sodium chloride, and 1 gram of potassium chloride.</item>
                     <item>
                        <caption>•</caption>Dose 2 Pouch A contains 40 grams of PEG 3350, 3.2 grams of sodium chloride, and 1.2 grams of potassium chloride.</item>
                     <item>
                        <caption>•</caption>Dose 2 Pouch B contains 48.11 grams of sodium ascorbate and 7.54 grams of ascorbic acid.</item>
                  </list>
               </text>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For Oral Solution: First dose: one pouch labeled Dose 1; Second dose: two pouches labeled Dose 2 Pouch A and Dose 2 Pouch B.</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Dose 1 contains 100 grams of polyethylene glycol (PEG) 3350, 9 grams of sodium sulfate, 2 grams of sodium chloride, and 1 gram of potassium chloride. (<linkHtml href="#ID_9cf9570b-3be8-4a00-82fd-0f1630c8e1cb">3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Dose 2 Pouch A contains 40 grams of PEG 3350, 3.2 grams of sodium chloride, and 1.2 grams of potassium chloride. (<linkHtml href="#ID_9cf9570b-3be8-4a00-82fd-0f1630c8e1cb">3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Dose 2 Pouch B contains 48.11 grams of sodium ascorbate and 7.54 grams of ascorbic acid. (<linkHtml href="#ID_9cf9570b-3be8-4a00-82fd-0f1630c8e1cb">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">
               <id root="86aebfba-2b45-446b-ae9d-8ee3436b86a8"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS </title>
               <text>
                  <paragraph>PLENVU is contraindicated in the following conditions:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Gastrointestinal (GI) obstruction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_f468e7cf-5d44-4259-b6dd-a138e395866e">5.6</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Bowel perforation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_f468e7cf-5d44-4259-b6dd-a138e395866e">5.6</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Gastric retention</item>
                     <item>
                        <caption>•</caption>Ileus</item>
                     <item>
                        <caption>•</caption>Toxic megacolon</item>
                     <item>
                        <caption>•</caption>Hypersensitivity to any ingredient in PLENVU <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3a6915b2-a296-4308-a1af-56963a8fee53">5.10</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Gastrointestinal (GI) obstruction (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>, <linkHtml href="#ID_f468e7cf-5d44-4259-b6dd-a138e395866e">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Bowel perforation (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>, <linkHtml href="#ID_f468e7cf-5d44-4259-b6dd-a138e395866e">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Gastric retention (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Ileus (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Toxic megacolon (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hypersensitivity to any ingredient in PLENVU (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>, <linkHtml href="#ID_3a6915b2-a296-4308-a1af-56963a8fee53">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_237227d3-3f3a-4698-97c2-34bbdbb8ae7a">
               <id root="8bcbc90c-626c-410e-86cd-019b6c9ac2ed"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS </title>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Risk of fluid and electrolyte abnormalities:</content> Encourage adequate hydration, assess concurrent medications, and consider laboratory assessments prior to and after use. (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>, <linkHtml href="#ID_76ff245f-c055-42f4-9cd9-802869bcbe60">5.2</linkHtml>, <linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Cardiac arrhythmias:</content> Consider pre-dose and post-colonoscopy ECGs in patients at increased risk. (<linkHtml href="#ID_76ff245f-c055-42f4-9cd9-802869bcbe60">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Seizures:</content> Use caution in patients with a history of seizures and patients at increased risk of seizure, including medications that lower the seizure threshold. (<linkHtml href="#ID_f31aa484-7b27-41f5-9332-1f12ea406930">5.3</linkHtml>, <linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Patients with renal impairment or taking concomitant medications that affect renal function:</content> Use caution, ensure adequate hydration and consider testing. (<linkHtml href="#ID_a43c3707-d1d3-45bd-94cd-7ae99309404c">5.4</linkHtml>, <linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>, <linkHtml href="#ID_e3807cd6-3e1d-4c26-888c-146c67b604e3">8.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Mucosal ulcerations</content>: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. (<linkHtml href="#ID_7e4b97f4-b4a3-4ad7-967a-58f9310e2477">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Suspected GI obstruction or perforation</content>: Rule out diagnosis before administration. (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>, <linkHtml href="#ID_f468e7cf-5d44-4259-b6dd-a138e395866e">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Patients at risk for aspiration</content>: Observe during administration. (<linkHtml href="#ID_892886fc-aca3-4a51-8852-e130088f448a">5.7</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Glucose-6-phosphate dehydrogenase deficiency (G6PD):</content> Use with caution. (<linkHtml href="#ID_01053379-704d-41a7-800a-25517fc08981">5.8</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Risks in patients with phenylketonuria</content>: Contains phenylalanine. (<linkHtml href="#ID_95f501ff-4751-4349-8feb-e08d439d85af">5.9</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Hypersensitivity reactions, including anaphylaxis:</content> Inform patients to seek immediate medical care if symptoms occur. (<linkHtml href="#ID_3a6915b2-a296-4308-a1af-56963a8fee53">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">
                     <id root="8b7fed86-3ea9-42ee-b7c6-7fe9ff944640"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Serious Fluid and Electrolyte Abnormalities </title>
                     <text>
                        <paragraph>Advise patients to hydrate adequately before, during, and after the use of PLENVU. If a patient develops significant vomiting or signs of dehydration after taking PLENVU, consider performing post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN).</paragraph>
                        <paragraph>Bowel preparations can cause fluid and electrolyte disturbances, which can lead to serious adverse reactions including cardiac arrhythmias, seizures, and renal impairment. Correct fluid and electrolyte abnormalities before treatment with PLENVU. PLENVU should be used with caution in patients using concomitant medications that increase the risk of electrolyte abnormalities [such as diuretics, angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)] <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)]</content>. Consider performing pre-dose and post-colonoscopy laboratory tests (sodium, potassium, calcium, creatinine, and BUN) in patients receiving these concomitant medications.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_76ff245f-c055-42f4-9cd9-802869bcbe60">
                     <id root="42db3191-577d-4edf-bcfc-e8492599f1ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Cardiac Arrhythmias  </title>
                     <text>
                        <paragraph>There have been rare reports of serious arrhythmias (including atrial fibrillation) associated with the use of ionic osmotic laxative products for bowel preparation. These occur predominantly in patients with underlying cardiac risk factors and electrolyte disturbances. Use caution when prescribing PLENVU for patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, cardiomyopathy or electrolyte imbalance). Consider pre-dose and post-colonoscopy ECGs in patients at increased risk of serious cardiac arrhythmias.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f31aa484-7b27-41f5-9332-1f12ea406930">
                     <id root="bbec7965-792b-445c-80cb-f62235779cd5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Seizures </title>
                     <text>
                        <paragraph>There have been rare reports of generalized tonic-clonic seizures and/or loss of consciousness associated with use of bowel preparation products in patients with no prior history of seizures. The seizure cases were associated with electrolyte abnormalities (e.g., hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia) and low serum osmolality. The neurologic abnormalities resolved with correction of fluid and electrolyte abnormalities.</paragraph>
                        <paragraph>Use caution when prescribing PLENVU for patients with a history of seizures and in patients at increased risk of seizure, such as patients taking medications that lower the seizure threshold (e.g., tricyclic antidepressants), patients withdrawing from alcohol or benzodiazepines, or patients with known or suspected hyponatremia. <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a43c3707-d1d3-45bd-94cd-7ae99309404c">
                     <id root="cb5be04e-e474-49c4-880c-fc04e644e677"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Use in Patients with Renal Impairment  </title>
                     <text>
                        <paragraph>Use PLENVU with caution in patients with renal impairment or patients taking concomitant medications that affect renal function (such as diuretics, ACE inhibitors, angiotensin receptor blockers, or nonsteroidal anti-inflammatory drugs) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)]</content>. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of PLENVU, and consider performing pre-dose and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#ID_e3807cd6-3e1d-4c26-888c-146c67b604e3">8.6</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7e4b97f4-b4a3-4ad7-967a-58f9310e2477">
                     <id root="a3656f80-47f2-4fea-afed-823ed0f0da19"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis </title>
                     <text>
                        <paragraph>Osmotic laxatives may produce colonic mucosal aphthous ulcerations, and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of stimulant laxatives and PLENVU may increase the risk and is not recommended. Consider the potential for mucosal ulcerations resulting from the bowel preparation when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f468e7cf-5d44-4259-b6dd-a138e395866e">
                     <id root="8338f1ff-067e-4793-aa5d-f68c043a684c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Use in Patients with Significant Gastrointestinal Disease </title>
                     <text>
                        <paragraph>If gastrointestinal obstruction or perforation is suspected, perform appropriate diagnostic studies to rule out these conditions before administering PLENVU <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>)]</content>. Use with caution in patients with severe ulcerative colitis.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_892886fc-aca3-4a51-8852-e130088f448a">
                     <id root="97c4698d-3ad7-4f94-b8d5-47410b277162"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Aspiration  </title>
                     <text>
                        <paragraph>Patients with impaired gag reflex or other swallowing abnormalities are at risk for regurgitation or aspiration of PLENVU. Observe these patients during the administration of PLENVU. Use with caution in these patients. </paragraph>
                        <paragraph>Do not combine PLENVU with starch-based thickeners [see Dosage and Administration (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>)]. Polyethylene glycol (PEG), a component of PLENVU, when mixed with starch-thickened liquids reduces the viscosity of the starch-thickened liquid. When a PEG-based product used for another indication was mixed in starch-based pre-thickened liquids used in patients with dysphagia, thinning of the liquid occurred and cases of choking and potential aspiration were reported.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_01053379-704d-41a7-800a-25517fc08981">
                     <id root="d3f99514-680b-4b39-8bef-a257f068e138"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency </title>
                     <text>
                        <paragraph>Since PLENVU contains sodium ascorbate and ascorbic acid, PLENVU should be used with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, especially G6PD deficiency patients with an active infection, with a history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_95f501ff-4751-4349-8feb-e08d439d85af">
                     <id root="00063e87-82df-4d0e-b543-a88c38a1532f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risks in Patients with Phenylketonuria </title>
                     <text>
                        <paragraph>Phenylalanine can be harmful to patients with phenylketonuria (PKU). PLENVU contains phenylalanine, a component of aspartame. Each PLENVU treatment contains 491 mg of phenylalanine. Before prescribing PLENVU to a patient with PKU, consider the combined daily amount of phenylalanine from all sources, including PLENVU.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3a6915b2-a296-4308-a1af-56963a8fee53">
                     <id root="1509cca9-be80-40d6-8c16-2a9f83807757"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Hypersensitivity Reactions </title>
                     <text>
                        <paragraph>PLENVU contains PEG and may cause serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#ID_9bdff903-238f-442f-8b42-ba8b431e27e8">6.1</linkHtml>, <linkHtml href="#ID_9fac12e3-34ee-4cf4-b6a4-5eb135aa3757">6.2</linkHtml>)]</content>. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_f5ad9b88-5098-4d24-b77d-c0b59461d002">
               <id root="f1043eeb-7baa-4996-862b-1b4db6ecab12"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS </title>
               <text>
                  <paragraph>The following serious or otherwise important adverse reactions for bowel preparations are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Serious Fluid and Electrolyte Abnormalities <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Cardiac Arrhythmias <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_76ff245f-c055-42f4-9cd9-802869bcbe60">5.2</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_f31aa484-7b27-41f5-9332-1f12ea406930">5.3</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Patients with Renal Impairment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_a43c3707-d1d3-45bd-94cd-7ae99309404c">5.4</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Colonic Mucosal Ulceration, Ischemic Colitis and Ulcerative Colitis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7e4b97f4-b4a3-4ad7-967a-58f9310e2477">5.5</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Patients with Significant Gastrointestinal Disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_f468e7cf-5d44-4259-b6dd-a138e395866e">5.6</linkHtml>)] </content>
                     </item>
                     <item>
                        <caption>•</caption>Aspiration <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_892886fc-aca3-4a51-8852-e130088f448a">5.7</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_01053379-704d-41a7-800a-25517fc08981">5.8</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Risks in Patients with Phenylketonuria <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_95f501ff-4751-4349-8feb-e08d439d85af">5.9</linkHtml>)]</content>
                     </item>
                     <item>
                        <caption>•</caption>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_3a6915b2-a296-4308-a1af-56963a8fee53">5.10</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (&gt;2%) are nausea, vomiting, dehydration and abdominal pain/discomfort. (<linkHtml href="#ID_9bdff903-238f-442f-8b42-ba8b431e27e8">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_9bdff903-238f-442f-8b42-ba8b431e27e8">
                     <id root="4e62fc3c-8b49-422a-a28b-61aa60e4edbc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The safety of PLENVU Two-Day Split Dosage and One-Day Morning Dosage regimens was evaluated in two randomized, parallel group, multicenter, investigator-blinded clinical trials (Two-Day Split Dosage in the NOCT and MORA trials and One-Day Morning Dosage in the MORA trial) in 1351 adult patients undergoing colonoscopy. The mean age of the study population was 56 years (range 18 to 86 years), 92% of patients were Caucasian and 51% were female. In the NOCT trial, 61% of patients had mild renal impairment. In the MORA trial, 67% had mild renal impairment and 5% had moderate renal impairment. Patients with severe renal impairment were not enrolled in the clinical trials of PLENVU <content styleCode="italics">[see Clinical Studies (<linkHtml href="#ID_0544cd4d-3656-4e0e-a781-6ab3fcf46800">14</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>The most common adverse reactions (&gt;2%) in the PLENVU treatment groups in both trials were: nausea, vomiting, dehydration and abdominal pain/discomfort. </paragraph>
                        <paragraph>Table 1 and Table 2 display adverse reactions reported in at least 1% of patients in one or more treatment group(s) in the NOCT and MORA trials, respectively. Since diarrhea was considered as a part of the efficacy assessment, it was not defined as an adverse reaction in these trials.</paragraph>
                        <table ID="_RefID0EM1AE" width="100%">
                           <caption>Table 1: Common Adverse Reactions* in Patients Undergoing Colonoscopy in the NOCT Trial by Treatment Group</caption>
                           <col width="33%"/>
                           <col width="33%"/>
                           <col width="33%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Preferred Term</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">PLENVU</content>
                                       <br/>
                                       <content styleCode="bold">Two-Day Split Dosage</content>
                                       <br/>
                                       <content styleCode="bold">Regimen</content>
                                       <br/>
                                       <content styleCode="bold">(N = 275)</content>
                                       <br/>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Trisulfate</content>
                                       <footnote ID="_Ref72839478">Trisulfate: Two 6-ounce bottles of oral solution each containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, magnesium sulfate 1.6 grams</footnote>
                                       <br/>
                                       <content styleCode="bold">Two-Day Split Dosage </content>
                                       <br/>
                                       <content styleCode="bold">Regimen</content>
                                       <br/>
                                       <content styleCode="bold">(N = 271)</content>
                                       <br/>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Vomiting </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dehydration<footnote ID="_Ref72839750">Includes signs and symptoms of dehydration, including dizziness, dry mouth, orthostatic hypotension, pre-syncope, syncope, and thirst</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abdominal Pain/Discomfort<footnote ID="_Ref72839765">Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal tenderness</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Decline in Glomerular Filtration Rate (GFR)<footnote ID="_Ref72839774">Decreased or abnormal GFR</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Electrolyte Abnormalities<footnote ID="_Ref72839784">Includes increased anion gap, decreased blood bicarbonate, hypomagnesemia, hyperosmolarity, hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyperosmolar state, hyperuricemia, hypocalcemia, and hypophosphatemia</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Fatigue</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abdominal Distension</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Gastritis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hiatus Hernia</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nasopharyngitis</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" valign="top">
                                    <paragraph>* Reported in at least 1% of patients in either treatment group</paragraph>
                                    <paragraph>N = Total number of patients in the treatment group</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Botrule " valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_RefID0ESCAG" width="100%">
                           <caption>Table 2: Common Adverse Reactions* in Patients Undergoing Colonoscopy in the MORA Trial by Treatment Group</caption>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Preferred Term</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">PLENVU</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">One-Day Morning</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage Regimen</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 271)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">PLENVU</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Two-Day Split</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage Regimen</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 265)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">2 Liter PEG +</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Electrolytes</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Two-Day Split</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Dosage Regimen</content>
                                       <footnote ID="_Ref72839985">2 Liter PEG Plus Electrolytes: Two doses each containing PEG 3350 100 grams, sodium sulfate 7.5 grams, sodium chloride 2.691 grams, potassium chloride 1.015 grams, sodium ascorbate 5.9 grams, and ascorbic acid 4.7 grams</footnote>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">(N = 269)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Vomiting</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Dehydration<footnote ID="_Ref72840311">Includes signs and symptoms of dehydration, including dizziness, dry mouth, orthostatic hypotension, pre-syncope, syncope, and thirst</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Abdominal Pain/Discomfort<footnote ID="_Ref72840324">Includes abdominal discomfort, abdominal pain, lower abdominal pain, upper abdominal pain, and abdominal tenderness</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Hypertension</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>Electrolyte Abnormalities<footnote ID="_Ref72840338">Includes increased anion gap, decreased blood bicarbonate, hypomagnesemia, increased blood osmolarity, hypokalemia, hyperkalemia, hypercalcemia, hypernatremia, hyperosmolar state, hyperuricemia, hypocalcemia, and hypophosphatemia</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" valign="top">
                                    <paragraph>* Reported in at least 1% of patients in either treatment group</paragraph>
                                    <paragraph>N = Total number of patients in the treatment group</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode="Botrule " valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Electrolyte Changes</content>
                        </paragraph>
                        <paragraph>Increases in serum sodium, chloride, calcium, magnesium, phosphate, and urate were noted in more patients treated with PLENVU compared with control in one or both trials. The majority of these changes were transient and not clinically significant. Associated decreases in bicarbonate and increases in serum osmolality were also noted.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Renal Function</content>
                        </paragraph>
                        <paragraph>Decreases in creatinine clearance and increases in blood urea nitrogen (BUN) were also noted in more patients treated with PLENVU compared to control in both trials. Changes of a magnitude indicative of possible acute renal injury, or worsening of baseline chronic renal impairment, were noted infrequently and occurred at a similar incidence in both PLENVU and comparator arms. </paragraph>
                        <paragraph>Adverse reactions in patients with mild renal impairment were similar to those in patients with normal renal function<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Less Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Less common adverse reactions (less than 1%) in the NOCT and MORA trials include: anorectal discomfort, hypersensitivity reaction (including rash), migraine, somnolence, asthenia, chills, pains, aches, palpitation, sinus tachycardia, hot flush, and transient increase in liver enzymes.</paragraph>
                        <paragraph>An additional 235 patients were exposed to the One-Day Morning Dosage Regimen of PLENVU in a third clinical trial, utilizing a comparator not approved in the United States. The adverse reaction profile for patients receiving PLENVU in that trial was similar to what is described above.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9fac12e3-34ee-4cf4-b6a4-5eb135aa3757">
                     <id root="05f740de-4f0f-472b-bccd-0eb70bf41dd2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of another oral formulation of polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride or other polyethylene glycol (PEG)-based bowel preparations. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity: </content>urticaria/rash, pruritus, dermatitis, rhinorrhea dyspnea, chest and throat tightness, fever, angioedema, anaphylaxis and anaphylactic shock <content styleCode="italics">[see Contraindications (<linkHtml href="#ID_b9eb633a-f764-48e2-ac04-79feab4a9d5f">4</linkHtml>)]</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular: </content>arrhythmia, atrial fibrillation, peripheral edema, asystole, and acute pulmonary edema after aspiration</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>upper gastrointestinal bleeding from a Mallory-Weiss tear, esophageal perforation [usually with gastroesophageal reflux disease (GERD)]</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system: </content>tremor, seizure</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b66a734c-b0c9-4592-831b-0b3a514aaffc">
               <id root="e1e74857-5c39-4704-9d06-45f745f17e8f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS </title>
               <effectiveTime value="20230901"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Drugs that increase risks due to fluid and electrolyte changes. (<linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_58d80f84-9161-4005-9762-ec41176de323">
                     <id root="55ae56da-fe5d-4f3a-af58-31b1b1f8211b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Drugs That May Increase Risks Due to Fluid and Electrolyte Abnormalities  </title>
                     <text>
                        <paragraph>Use caution when prescribing PLENVU for patients with conditions and/or who are using medications that increase the risk of fluid and electrolyte disturbances or may increase the risk of renal impairment, seizures, arrhythmias, or QT prolongation in the setting of fluid and electrolyte abnormalities <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>, <linkHtml href="#ID_76ff245f-c055-42f4-9cd9-802869bcbe60">5.2</linkHtml>, <linkHtml href="#ID_f31aa484-7b27-41f5-9332-1f12ea406930">5.3</linkHtml>, <linkHtml href="#ID_a43c3707-d1d3-45bd-94cd-7ae99309404c">5.4</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Consider additional patient evaluations as appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0cc1ef6e-42ba-4dcf-9cfa-fc515bf1533a">
                     <id root="caad8224-c361-48f2-8de4-8e040518efde"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Potential for Reduced Drug Absorption </title>
                     <text>
                        <paragraph>PLENVU can reduce the absorption of other coadministered oral drugs<content styleCode="italics">. </content>Administer oral medications at least 1 hour before starting each dose of PLENVU <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#ID_8926f07b-fec6-4280-a270-d3ebc7a06085">2.1</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6de28110-c4aa-4f61-b789-1aea39c8804d">
                     <id root="b91d1e0e-7237-4fb7-84b4-818b0f6a4c3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Stimulant Laxatives </title>
                     <text>
                        <paragraph>Concurrent use of stimulant laxatives and PLENVU may increase the risk of mucosal ulceration or ischemic colitis. Avoid use of stimulant laxatives (e.g., bisacodyl, sodium picosulfate) while taking PLENVU <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_7e4b97f4-b4a3-4ad7-967a-58f9310e2477">5.5</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_32a7b844-43c8-425c-a657-c37bee8317d9">
               <id root="8422f587-b8ea-4b8e-8c84-2df14f3081d1"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS </title>
               <effectiveTime value="20230901"/>
               <component>
                  <section ID="ID_034a13e8-c154-4bcd-927a-1ea8ca89e4ce">
                     <id root="45f29d11-2c3a-46fe-8e38-4f1a1f42748b"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data with PLENVU in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Animal reproduction studies have not been conducted with PLENVU. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e4d02e4f-3841-464a-a099-ed8642711973">
                     <id root="3fe3774c-9093-4c2a-89b7-0e1f008f8aa6"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data available to assess the presence of PLENVU in human milk, the effects on the breastfed child or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of PLENVU to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PLENVU and any potential adverse effects on the breastfed child from PLENVU or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_729eca48-d75f-427d-8152-272c6e0f4f7d">
                     <id root="8b0f5081-8147-4fb8-97f6-8335ba4c26a4"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use </title>
                     <text>
                        <paragraph>The safety and effectiveness of PLENVU in pediatric patients has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_74ac4efc-a295-4453-a353-4cb7bb949e17">
                     <id root="b1c0e4b0-d070-4632-b14b-1def13b38701"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use </title>
                     <text>
                        <paragraph>Of the approximately 1,000 patients in clinical trials receiving PLENVU, 217 (21%) patients were over 65 years of age. No overall differences in safety or effectiveness were observed between geriatric patients and younger patients, and other reported clinical experience has not identified differences in responses between geriatric patients and younger patients. However, elderly patients are more likely to have decreased hepatic, renal or cardiac function and may be more susceptible to adverse reactions resulting from fluid and electrolyte abnormalities <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e3807cd6-3e1d-4c26-888c-146c67b604e3">
                     <id root="00b99657-5dbe-48a0-abfb-17abe6e2437b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment </title>
                     <text>
                        <paragraph>Use PLENVU with caution in patients with renal impairment or patients taking concomitant medications that may affect renal function <content styleCode="italics">[see Drug Interactions (<linkHtml href="#ID_58d80f84-9161-4005-9762-ec41176de323">7.1</linkHtml>)]</content>. These patients may be at risk for renal injury. Advise these patients of the importance of adequate hydration before, during and after the use of PLENVU, and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_a43c3707-d1d3-45bd-94cd-7ae99309404c">5.4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_57f327c7-33ec-4010-a3c9-65727aa143f1">
               <id root="59478900-4738-4f36-ac27-0feed7847625"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE </title>
               <text>
                  <paragraph>Overdosage of more than the recommended dose of PLENVU may lead to severe electrolyte disturbances, as well as dehydration and hypovolemia, with signs and symptoms of these disturbances <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#ID_feb1e19b-a8b9-4853-8222-732c7cfe0b65">5.1</linkHtml>)]</content>. Monitor for fluid and electrolyte disturbances and treat symptomatically.</paragraph>
               </text>
               <effectiveTime value="20230901"/>
            </section>
         </component>
         <component>
            <section ID="ID_981313a5-4316-455c-a8d6-04343390df83">
               <id root="2906b84a-a722-4f20-b8e1-b1eddda8dae3"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION </title>
               <text>
                  <paragraph>The active ingredients contained in PLENVU are provided in Table 3.</paragraph>
                  <table ID="_RefID0E1TAG" width="100%">
                     <caption>Table 3: Details of Active Ingredients contained in PLENVU</caption>
                     <col width="14%"/>
                     <col width="11%"/>
                     <col width="12%"/>
                     <col width="63%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Chemical Name</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Chemical Formula</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Average Molecular Weight (g/mol)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Chemical Structure</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Polyethylene Glycol (PEG) 3350</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>H-(OCH<sub>2</sub>-CH<sub>2</sub>)<sub>n</sub>-OH</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>3350</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id594216362" referencedObject="D71502EA-740B-46A5-845B-DA72300D7073">
                                 <caption>Table 3: Details of Active Ingredients contained in PLENVU</caption>
                              </renderMultiMedia>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Sodium Ascorbate</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>C<sub>6</sub>H<sub>7</sub>NaO<sub>6</sub>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>198.1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id542024632" referencedObject="B58CFBE5-A7CF-4032-84C9-ABBF77116011">
                                 <caption>Table 3: Details of Active Ingredients contained in PLENVU</caption>
                              </renderMultiMedia>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Sodium Sulfate</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Na<sub>2</sub>SO<sub>4</sub>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>142.0</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-929813934" referencedObject="F5CA285F-3432-4B21-BB60-AF1AAC6B746F">
                                 <caption>Table 3: Details of Active Ingredients contained in PLENVU</caption>
                              </renderMultiMedia>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>Ascorbic Acid</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>C<sub>6</sub>H<sub>8</sub>O<sub>6</sub>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>176.1</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <renderMultiMedia ID="id-655845151" referencedObject="F6F9CCFD-86F2-480F-94B2-27BCF12AFF03">
                                 <caption>Table 3: Details of Active Ingredients contained in PLENVU</caption>
                              </renderMultiMedia>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Sodium Chloride</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>NaCl</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>58.4</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Na<sup>+</sup> Cl<sup>-</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Potassium Chloride</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>KCl</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>74.6</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>K<sup>+</sup> Cl<sup>+</sup>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is an osmotic laxative consisting of three pouches (one for Dose 1, one for Dose 2 Pouch A and one for Dose 2 Pouch B) containing white to yellow powder for reconstitution.</paragraph>
                  <paragraph>Dose 1 contains 100 grams of PEG 3350, 9 grams of sodium sulfate, 2 grams of sodium chloride, and 1 gram of potassium chloride, and the following excipients: sucralose, encapsulated citric acid and mango flavoring. When Dose 1 is dissolved in water to a volume of 16 fluid ounces, PLENVU Dose 1 (PEG 3350, sodium sulfate, sodium chloride and potassium chloride) is an oral solution having a mango flavor.</paragraph>
                  <paragraph>Each Dose 2 Pouch A contains 40 grams of PEG 3350, 3.2 grams of sodium chloride, and 1.2 grams of potassium chloride, and the following excipients: aspartame and fruit punch flavoring. </paragraph>
                  <paragraph>Each Dose 2 Pouch B contains 48.11 grams of sodium ascorbate and 7.54 grams of ascorbic acid.</paragraph>
                  <paragraph>When Dose 2 Pouch A and Dose 2 Pouch B are dissolved together in water to a volume of 16 fluid ounces, PLENVU Dose 2 (sodium ascorbate, PEG 3350, ascorbic acid, sodium chloride and potassium chloride) is an oral solution having a fruit punch flavor.</paragraph>
                  <paragraph>The entire reconstituted 32 fluid ounces of PLENVU bowel preparation contains 140 grams of PEG 3350, 48.11 grams of sodium ascorbate, 9 grams of sodium sulfate, 7.54 grams of ascorbic acid, 5.2 grams of sodium chloride and 2.2 grams of potassium chloride and the following excipients: aspartame, sucralose, encapsulated citric acid, mango and fruit punch flavorings.</paragraph>
                  <paragraph>A mixing container for reconstitution is enclosed.</paragraph>
                  <paragraph>Phenylketonurics: Contains Phenylalanine 491 mg per treatment.</paragraph>
                  <paragraph>Contains no ingredient made from a gluten-containing grain (wheat, barley, or rye).</paragraph>
               </text>
               <effectiveTime value="20230901"/>
               <component>
                  <observationMedia ID="D71502EA-740B-46A5-845B-DA72300D7073">
                     <text>table3image1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="B58CFBE5-A7CF-4032-84C9-ABBF77116011">
                     <text>table3image2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="F5CA285F-3432-4B21-BB60-AF1AAC6B746F">
                     <text>table3image3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="F6F9CCFD-86F2-480F-94B2-27BCF12AFF03">
                     <text>table3image4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_dbb86a64-b2c6-4b7f-866f-6f21a452150c">
               <id root="095d8f32-43ab-44a1-8b4a-5c9db1733cac"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY </title>
               <effectiveTime value="20230901"/>
               <component>
                  <section ID="ID_fa9c1a9f-f45e-43f9-844c-06c745a5ff04">
                     <id root="b136a336-dce5-47c5-9d4d-982f4d11521d"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action </title>
                     <text>
                        <paragraph>The primary mode of action is osmotic action of the components of PLENVU (PEG 3350 plus sodium sulfate components in Dose 1, and sodium ascorbate and ascorbic acid plus PEG 3350 components in Dose 2) which induce the laxative effect. The physiological consequence is increased water retention in the lumen of the colon, resulting in loose stools.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_eeba2b0f-dbc9-4e9c-9ff1-7a21ef2d4aae">
                     <id root="57eab17e-39a2-4543-a842-03d1f837f8d6"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics </title>
                     <text>
                        <paragraph>The osmotic effect of the unabsorbed PEG, ascorbate and sulfate ions, when ingested, produces a copious watery diarrhea.</paragraph>
                        <paragraph>The first bowel movement may happen about 1 to 2 hours after the start of PLENVU intake.</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_77212473-3ee0-4fd8-bb7e-d101d7467690">
                     <id root="415a1939-948f-4e6f-978e-d43d20ed1e8d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>The plasma pharmacokinetic parameters for PEG 3350, ascorbate and sulfate are shown in Table 4.</paragraph>
                        <table ID="_RefID0EM4AG" width="100%">
                           <caption>Table 4: Plasma Pharmacokinetic Data Following Two-Day Split Dosage Regimen of 140 grams PEG 3350, 33.9 grams Sodium Ascorbate, 9 grams Sodium Sulfate, 20.1 grams Ascorbic Acid, 4.8 grams Sodium Chloride and 2.3 grams Potassium Chloride in Healthy Subjects<footnote ID="_Ref145595919">Four-day study with controlled diet including fasting from 2 pm on Day 1 to 2 pm on Day 2.</footnote> (N=21)<footnote ID="_Ref145595946">Product studied contains the same amount of PEG 3350 and sodium sulfate, although the amount of sodium ascorbate and ascorbic acid are slightly different, compared to PLENVU.</footnote>
                           </caption>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">PK Parameter</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">PEG 3350</content>
                                       <br/>
                                       <content styleCode="bold">Mean (SD)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Ascorbate</content>
                                       <footnote ID="_Ref145595993">Baseline-corrected</footnote>
                                       <br/>
                                       <content styleCode="bold">Mean (SD)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Sulfate</content>
                                       <footnoteRef IDREF="_Ref145595993"/>
                                       <br/>
                                       <content styleCode="bold">Mean (SD)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>C<sub>max</sub> [mcg/mL]</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>2.7 (1.17)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>70.8 (22.37)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>17.6 (4.80)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>T<sub>max</sub> [h]</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>3.0 (0.61)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>16.8 (0.75)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>8.1 (5.51)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>AUC(0-t<sub>last</sub>)<br/>[mcg●h/mL]</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>17.3 (7.19)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>433.1 (157.29)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>206.2 (74.32)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>V<sub>d</sub> [l]</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>48,481 (29,811)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,026 (675)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>231 (205)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>t<sub>1/2</sub> [h]</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>4.1 (2.34)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>7.2 (6.16)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>10.5 (15.19)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>SD = standard deviation; C<sub>max</sub> = maximum concentration; T<sub>max</sub> = time to maximum concentration from start of dosing; AUC(0-t<sub>last</sub>) = area under the curve from t<sub>0 </sub>to t<sub>last</sub>; V<sub>d</sub> = volume of distribution; t<sub>1/2</sub> = half-life.</paragraph>
                        <paragraph>A pharmacokinetic study measured up to 85% to 99% of a 140 grams oral PEG 3350 dose in excreted feces.</paragraph>
                        <paragraph>A pharmacokinetic study measured up to 69% of a 50 grams oral ascorbate dose in excreted feces and up to 5% of the 50 grams oral ascorbate dose is recovered in the urine (with up to 0.07% as the ascorbate metabolite, oxalic acid).</paragraph>
                        <paragraph>Sulfate is endogenous and also present in the diet. A pharmacokinetic study measured up to 69% to 73% of a 9 grams oral sodium sulfate dose in excreted feces, with approximately 43% recovered in the urine.</paragraph>
                        <paragraph>Following a One-Day Morning Dosage regimen of PLENVU, C<sub>max</sub> values of glycolic acid (after baseline correction) ranged from 76 to 1,770 ng/mL with a median T<sub>max</sub> of 9 hours and AUC<sub>0-last </sub>in the range of 3,770 to 17,700 ng●h/mL. The concentrations of ethylene glycol and diethylene glycol in any individual subject were lower than 2.5 mcg/mL (lower limit of quantitation (LLOQ): 2.5 mcg/mL) and oxalic acid was not measurable (LLOQ: 10 mcg/mL).</paragraph>
                     </text>
                     <effectiveTime value="20230901"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0544cd4d-3656-4e0e-a781-6ab3fcf46800">
               <id root="3e9f4d45-861c-49c5-a23c-46e1d509133b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Study Design</content>
                  </paragraph>
                  <paragraph>The colon cleansing efficacy, safety and tolerability of PLENVU was evaluated in two randomized, parallel-group, multicenter, investigator-blinded trials in adult patients scheduled to undergo a screening, surveillance, or diagnostic colonoscopy. The overall patient population consisted of 49% male and 51% female patients, mean age of 56 years (range 18 to 86 years), 92% Caucasian, 5% Black and 2% Asian. In general, the demographic characteristics were balanced across the trials.</paragraph>
                  <paragraph>In Study NER1006-01/2014 (referred to as NOCT; NCT02254486) and Study NER1006-02/2014 (referred to as MORA; NCT02273167), the bowel cleansing efficacy of PLENVU was compared to two different comparators (see Table 5) using two different PLENVU dosing regimen(s):</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>PLENVU Two-Day Split Dosage regimen allows for an overnight gap between doses (Dose 1 taken in the evening before the colonoscopy, between approximately 4 pm and 8 pm, and Dose 2 the next morning, on the day of the colonoscopy, approximately 12 hours after the start of Dose 1).</item>
                     <item>
                        <caption>•</caption>PLENVU One-Day Morning Dosage regimen gives both doses the morning of the day of colonoscopy (Dose 1 between approximately 3 am and 7 am, and Dose 2 a minimum of 2 hours after the start of Dose 1).</item>
                  </list>
                  <table ID="_RefID0EKFBG" width="100%">
                     <caption>Table 5: Treatment Regimens by Trial</caption>
                     <col width="33%"/>
                     <col width="33%"/>
                     <col width="33%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Trial</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PLENVU Dosage Regimen(s)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Comparator Regimens</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>NOCT</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>Two-Day Split Dosage</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="underline">Trisulfate bowel cleansing solution</content>
                                 <br/>administered as a Two-Day Split Dosage regimen:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>[Trisulfate (Two 6-ounce bottles each containing sodium sulfate 17.5 grams, potassium sulfate 3.13 grams, and magnesium sulfate 1.6 grams)]</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>MORA</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Two-Day Split Dosage<br/>
                                 <br/>and<br/>
                                 <br/>One-Day Morning Dosage</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="underline">2 liter PEG + electrolytes (2 L PEG+E) preparation</content>
                                 <br/>administered as a Two-Day Split Dosage regimen:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Two doses, each containing PEG 3350 100 grams, sodium sulfate 7.5 grams, sodium chloride 2.691 grams, potassium chloride 1.015 grams, sodium ascorbate 5.9 grams, and ascorbic acid 4.7 grams</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Primary Endpoint</content>
                  </paragraph>
                  <paragraph>The primary efficacy endpoint in both trials was the proportion of patients achieving “overall bowel cleansing success,” which was defined by a result of Grade A or B (Grades A or B [see Table 6] corresponding to full visualization of the bowel mucosa on the Harefield Cleansing Scale [HCS]), as assessed on withdrawal of colonoscope. The HCS segmental scores were initially evaluated by the colonoscopist at the site, who was blinded to treatment, and evaluated for endpoint analysis by central readers (gastroenterologists) using video recordings of the colonoscopy.</paragraph>
                  <table ID="_RefID0ERHBG" width="100%">
                     <caption>Table 6: Harefield Cleansing Scale</caption>
                     <col width="50%"/>
                     <col width="50%"/>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5" styleCode="Botrule" valign="top">* Colon ascendens, Colon transversum, Colon descendens, Colon sigmoideum, Rectum</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Overall Grade</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Description</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>A</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>All five segments* scored 3 or 4<br/>(Mucosa is fully visualized without cleaning.)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>B</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>One or more segments scored 2, remaining segments<br/>scored 3 or 4<br/>(Mucosa is fully visualized.)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>C</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>One or more segments scored 1, remaining segments<br/>scored 2, 3 or 4</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>D</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>One or more segments scored 0</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Segmental Score</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Description</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>4</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>Empty and clean</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>3</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>Clear liquid</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>2</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>Brown liquid/fully removable semisolid stools</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule " valign="top">
                              <paragraph>1</paragraph>
                           </td>
                           <td styleCode="Rrule Lrule " valign="top">
                              <paragraph>Semisolid, only partially removable stools</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>0</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>Irremovable, heavy, hard stools </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Statistical Analysis</content>
                     <br/>The modified Intent-to-Treat (mITT) population was used as the primary population for the efficacy analyses and was defined as all randomized patients with the exception of any patient who (i) was randomized but subsequently failed to meet entry criteria and (ii) in whom it was confirmed (from their patient diary) that the same patient did not receive any study drug.</paragraph>
                  <paragraph>Non-inferiority was assessed using a one-sided 97.5% confidence interval (CI) for the difference in proportions of patients for the overall bowel cleansing success endpoint. Non-inferiority was demonstrated if the difference between PLENVU and the comparator was above the predefined non-inferiority margin set at -10%. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Efficacy Results</content>
                     <br/>The results for the overall bowel cleansing success endpoint in the mITT population in NOCT are shown in Table 7. The Two-Day Split Dosage regimen of PLENVU was shown to be non-inferior (NI) to the trisulfate solution comparator.</paragraph>
                  <table ID="_RefID0EOMBG" width="100%">
                     <caption>Table 7: Overall Bowel Cleansing Success Rate of PLENVU versus Trisulfate in NOCT</caption>
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Primary Endpoint</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=556)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PLENVU</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Two-Day</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Split Dosage Regimen</content>
                                 <br/>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=276)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n (% = n/N*100)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Trisulfate</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Two-Day</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Split Dosage Regimen</content>
                                 <br/>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(N=280)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">n (% = n/N*100)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PLENVU<sup>®</sup> - Trisulfate</content>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">Difference (%)</content>
                                 <br/>
                                 <br/>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(97.5% One-Sided Lower</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Confidence Interval)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Overall Colon</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Cleansing Success</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Rate</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>235</paragraph>
                              <paragraph>(85.1%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>238</paragraph>
                              <paragraph>(85.0%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>0.1%</paragraph>
                              <paragraph>(-8.2%)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The results for the overall bowel cleansing success endpoint in the mITT population in MORA are shown in Table 8. Both the PLENVU Two-Day Split Dosage regimen and the PLENVU One-Day Morning Dosage regimen were shown to be non-inferior (NI) to the 2 L PEG+E treatment comparator.</paragraph>
                  <table ID="_RefID0EGQBG" width="100%">
                     <caption>Table 8: Overall Bowel Cleansing Success Rate of PLENVU versus 2 L PEG+E in MORA</caption>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="20%"/>
                     <col width="18%"/>
                     <col width="21%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Primary </content>
                                 <br/>
                                 <content styleCode="bold">Endpoint</content>
                                 <br/>
                                 <content styleCode="bold">(N=822)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PLENVU</content>
                                 <br/>
                                 <content styleCode="bold">Two-Day</content>
                                 <br/>
                                 <content styleCode="bold">Split Dosage Regimen</content>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">(N=275)</content>
                                 <br/>
                                 <content styleCode="bold">n (% = n/N*100)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PLENVU</content>
                                 <br/>
                                 <content styleCode="bold">One-Day</content>
                                 <br/>
                                 <content styleCode="bold">Morning Dosage Regimen</content>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">(N=275)</content>
                                 <br/>
                                 <content styleCode="bold">n (% = n/N*100)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">2 L PEG+E</content>
                                 <br/>
                                 <content styleCode="bold">Two-Day</content>
                                 <br/>
                                 <content styleCode="bold">Split Dosage Regimen</content>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">(N=272)</content>
                                 <br/>
                                 <content styleCode="bold">n (% = n/N*100)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">PLENVU<sup>®</sup>
                                 </content>
                                 <br/>
                                 <content styleCode="bold">Regimen - 2 L</content>
                                 <br/>
                                 <content styleCode="bold">PEG+E</content>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">Difference (%)</content>
                                 <br/>
                                 <br/>
                                 <content styleCode="bold">(97.5% One-Sided Lower Confidence Interval)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">Overall Colon</content>
                                 <br/>
                                 <content styleCode="bold">Cleansing</content>
                                 <br/>
                                 <content styleCode="bold">Success Rate</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>253<br/>(92.0%)</paragraph>
                           </td>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>245<br/>(89.1%)</paragraph>
                           </td>
                           <td align="center" rowspan="4" styleCode="Rrule Lrule Botrule " valign="middle">
                              <paragraph>238<br/>(87.5%)</paragraph>
                           </td>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Two-Day </content>
                                 <br/>
                                 <content styleCode="bold">Split Dosage</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>4.5%<br/>(-4.0%)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">One-Day </content>
                                 <br/>
                                 <content styleCode="bold">Morning Dosage</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>1.6%<br/>(-6.9%)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20230901"/>
            </section>
         </component>
         <component>
            <section ID="ID_e6ccc70e-c276-4356-9d15-f097accd9564">
               <id root="c7d1e956-3865-4417-82c4-5ad020140d5c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING </title>
               <text>
                  <paragraph>PLENVU (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is supplied as a white to yellow powder for reconstitution.</paragraph>
                  <paragraph>Dose 1 contains 100 grams of PEG 3350, 9 grams of sodium sulfate, 2 grams of sodium chloride, and 1 gram of potassium chloride: NDC 65649-400-01.</paragraph>
                  <paragraph>Dose 2 Pouch A contains 40 grams of PEG 3350, 3.2 grams of sodium chloride, and 1.2 grams of potassium chloride: NDC 65649-400-01.</paragraph>
                  <paragraph>Dose 2 Pouch B contains 48.11 grams of sodium ascorbate and 7.54 grams of ascorbic acid: NDC 65649-400-01.</paragraph>
                  <paragraph>PLENVU, single-use inner carton: The inner carton contains three pouches labeled Dose 1, Dose 2 Pouch A and Dose 2 Pouch B: NDC 65649-400-01.</paragraph>
                  <paragraph>PLENVU, single-use outer carton: Each outer carton contains the inner carton, prescribing information and patient information and a disposable mixing container with lid for reconstitution of PLENVU: NDC 65649-400-01.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage</content>
                  </paragraph>
                  <paragraph>Store pack at room temperature, between 68°F to 77°F (20°C to 25°C) with excursions permitted to 59°F to 86°F (15°C to 30°C) [see USP Controlled Room Temperature]. The pack may be stored in a refrigerator.</paragraph>
               </text>
               <effectiveTime value="20230901"/>
            </section>
         </component>
         <component>
            <section ID="ID_8dd00f67-37f0-4f04-aad9-39533ba160a0">
               <id root="762533c9-90aa-4c35-90a6-748e32950df1"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).</paragraph>
                  <paragraph>Instruct patients:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Two doses of PLENVU are required for a complete preparation for colonoscopy either as a Two-Day Split Dosage or One-Day Morning Dosage regimen <content styleCode="italics">[see Instructions for Use].</content>
                     </item>
                     <item>
                        <caption>•</caption>Follow the directions in the <content styleCode="italics">Instructions for Use</content>, for either the Two-Day Split Dosage or the One-Day Morning Dosage regimen, as prescribed.</item>
                     <item>
                        <caption>•</caption>Reconstitute each pouch of PLENVU in the mixing container with water before ingestion and drink additional clear liquids. Examples of clear liquids can be found in the <content styleCode="italics">Instructions for Use. </content>Do not reconstitute with other liquids and/or add starch-based thickeners to the mixing container <content styleCode="italics">[see Warnings and Precautions (5.7)].</content>
                     </item>
                     <item>
                        <caption>•</caption>Consume additional clear liquids before, during, and after the use of PLENVU to prevent dehydration <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</item>
                     <item>
                        <caption>•</caption>Consume only clear liquids (no solid food) from the start of PLENVU treatment until after the colonoscopy.</item>
                     <item>
                        <caption>•</caption>Do not eat or drink alcohol, milk, anything colored red or purple or any other foods containing pulp material.</item>
                     <item>
                        <caption>•</caption>Do not take other laxatives while taking PLENVU.</item>
                     <item>
                        <caption>•</caption>PLENVU contains 491 mg of phenylalanine per treatment <content styleCode="italics">[see Warnings and Precautions (5.9)]</content>.</item>
                     <item>
                        <caption>•</caption>Administer oral medications at least 1 hour before starting each dose of PLENVU.</item>
                     <item>
                        <caption>•</caption>Contact their healthcare provider if they develop significant vomiting or signs of dehydration after taking PLENVU or if they experience altered consciousness or seizures <content styleCode="italics">[see Warnings and Precautions (5.1, 5.2, 5.3, 5.4)].</content>
                     </item>
                     <item>
                        <caption>•</caption>Stop drinking PLENVU temporarily or drink each portion at longer intervals if severe abdominal discomfort or distention develops until these symptoms diminish. If severe symptoms persist, contact their healthcare provider.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>Salix Pharmaceuticals, a division of<br/>Bausch Health US, LLC<br/>Bridgewater, NJ 08807 USA</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>Norgine Limited<br/>7 Tir-y-berth Industrial Estate<br/>New Road, Tir-y-berth<br/>Hengoed, CF82 8SJ<br/>United Kingdom (GBR)</paragraph>
                  <paragraph>Patented. See https://patents.salix.com for US patent information.</paragraph>
                  <paragraph>PLENVU is a registered trademark of the Norgine group of companies used under license.</paragraph>
                  <paragraph>© 2023 Salix Pharmaceuticals, Inc. or its affiliates</paragraph>
                  <paragraph>9643003</paragraph>
               </text>
               <effectiveTime value="20230901"/>
            </section>
         </component>
         <component>
            <section ID="ID_da4f2e4c-9c96-4166-af55-6bb6b0cfa0cb">
               <id root="ba59f1d8-c130-4472-bcb5-9437e2705c32"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>Medication Guide </title>
               <text>
                  <table width="100%">
                     <col width="8%"/>
                     <col width="22%"/>
                     <col width="22%"/>
                     <col width="25%"/>
                     <col width="25%"/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="5" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE</content>
                                 <br/>
                                 <content styleCode="bold">PLENVU<sup>®</sup> (plen-vu)</content>
                                 <br/>
                                 <content styleCode="bold">(polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride </content>
                                 <br/>
                                 <content styleCode="bold">and potassium chloride for oral solution)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Read this Medication Guide and Instructions for Use before your colonoscopy and again before you start taking PLENVU.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about PLENVU?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">PLENVU and other bowel preparations can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Serious loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood. These changes can cause:</content>
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>abnormal heartbeats that can cause death.</item>
                                       <item>
                                          <caption>•</caption>seizures. This can happen even if you have never had a seizure.</item>
                                       <item>
                                          <caption>•</caption>kidney problems.</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Your chance of having fluid loss and changes in body salts with PLENVU is higher if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption> </caption>
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>have heart problems.</item>
                                       <item>
                                          <caption>•</caption>have kidney problems.</item>
                                       <item>
                                          <caption>•</caption>take water pills (diuretics), high blood pressure medicine or non-steroidal anti-inflammatory drugs (NSAIDs).</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider right away if you have any of these symptoms of serious loss of body fluid (dehydration) while taking PLENVU:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="2" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>vomiting</item>
                                 <item>
                                    <caption>•</caption>dizziness</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>urinating less often than normal</item>
                                 <item>
                                    <caption>•</caption>headache</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>See <content styleCode="bold">“What are the possible side effects of PLENVU?” </content>for more information about side effects.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What is PLENVU?</content>
                                 <br/>PLENVU is a prescription medicine used by adults to clean the colon before a colonoscopy. PLENVU cleans your colon by causing you to have diarrhea (loose stools). Cleaning your colon helps your healthcare provider see the inside of your colon more clearly during your colonoscopy.<br/>It is not known if PLENVU is safe and effective in children.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Do not take PLENVU if your healthcare provider has told you that you have:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>a blockage in your intestine (bowel obstruction).</item>
                                 <item>
                                    <caption>•</caption>an opening in the wall of your stomach or intestine (bowel perforation).</item>
                                 <item>
                                    <caption>•</caption>problems with food and fluid emptying from your stomach (gastric retention).</item>
                                 <item>
                                    <caption>•</caption>a problem with food moving too slowly through your intestines (ileus).</item>
                                 <item>
                                    <caption>•</caption>a very dilated intestine (toxic megacolon).</item>
                                 <item>
                                    <caption>•</caption>an allergy to any of the ingredients in PLENVU. See the end of this Medication Guide for a complete list of ingredients in PLENVU.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Before taking PLENVU, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>have problems with serious loss of body fluid (dehydration) and changes in blood salts (electrolytes).</item>
                                 <item>
                                    <caption>•</caption>have heart problems.</item>
                                 <item>
                                    <caption>•</caption>have seizures or take medicines for seizures.</item>
                                 <item>
                                    <caption>•</caption>have kidney problems or take medicines for kidney problems.</item>
                                 <item>
                                    <caption>•</caption>have stomach or bowel problems, including ulcerative colitis.</item>
                                 <item>
                                    <caption>•</caption>have problems with swallowing, gastric reflux or if you inhale food or fluid into your lungs when eating or drinking (aspirate).</item>
                                 <item>
                                    <caption>•</caption>have a condition called glucose-6-phosphate dehydrogenase (G6PD) deficiency that destroys red blood cells.</item>
                                 <item>
                                    <caption>•</caption>are withdrawing from drinking alcohol.</item>
                                 <item>
                                    <caption>•</caption>have phenylketonuria (PKU). PLENVU contains phenylalanine.</item>
                                 <item>
                                    <caption>•</caption>are allergic to any of the ingredients in PLENVU.</item>
                                 <item>
                                    <caption>•</caption>are pregnant or plan to become pregnant. It is not known if PLENVU will harm your unborn baby. Talk to your healthcare provider if you are pregnant.</item>
                                 <item>
                                    <caption>•</caption>are breastfeeding or plan to breastfeed. It is not known if PLENVU passes into your breast milk. You and your healthcare provider should decide if you will take PLENVU while breastfeeding.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your </content>healthcare provider<content styleCode="bold"> about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">PLENVU may affect how other medicines work. </content>If you need to take any other medicines by mouth, take those medicines at least 1 hour before starting each dose of PLENVU.</paragraph>
                              <paragraph>Especially tell your healthcare provider if you take:</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>medicines to treat a blood salt (electrolyte) imbalance.</item>
                                 <item>
                                    <caption>•</caption>medicines for blood pressure or heart problems.</item>
                                 <item>
                                    <caption>•</caption>medicines for seizures (antiepileptics).</item>
                                 <item>
                                    <caption>•</caption>medicines for kidney problems.</item>
                                 <item>
                                    <caption>•</caption>water pills (diuretics).</item>
                                 <item>
                                    <caption>•</caption>non-steroidal anti-inflammatory drugs (NSAIDs).</item>
                                 <item>
                                    <caption>•</caption>laxatives. Do not take other laxatives while taking PLENVU.</item>
                                 <item>
                                    <caption>•</caption>medicines for depression or other mental health problems.</item>
                                 <item>
                                    <caption>•</caption>starch based thickeners. For patients who have trouble swallowing, do not mix PLENVU with starch-based thickeners </item>
                              </list>
                              <paragraph>Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure if you are taking any of the medicines listed above.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I take PLENVU?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">See the Instructions for Use for dosing instructions. </content>You must read, understand, and follow these instructions to take PLENVU the right way.</paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Take PLENVU exactly as your healthcare provider tells you to take it. Your healthcare provider will tell you to take the Two-Day Split Dosage option or the One-Day Morning Dosage option.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Drink clear liquids before, during, and after you take PLENVU, up until 2 hours before your colonoscopy, to help prevent fluid loss (dehydration) and changes in blood salt (electrolyte) levels.</content>
                                 </item>
                                 <item>
                                    <caption>•</caption>Do not eat solid food while taking PLENVU until after your colonoscopy.</item>
                                 <item>
                                    <caption>•</caption>It is important for you to drink the additional amount of clear liquids listed in the <content styleCode="bold">Instructions for Use</content>.</item>
                                 <item>
                                    <caption>•</caption>You may have stomach-area (abdomen) bloating after your first dose of PLENVU.<list listType="unordered">
                                       <item>
                                          <caption>•</caption>If you have severe stomach-area (abdomen) discomfort or bloating, stop drinking PLENVU for a short time or wait a longer time between each dose of PLENVU until your stomach-area symptoms improve. If your stomach‑area discomfort or bloating continues, tell your healthcare provider.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <caption>•</caption>Your first bowel movement may happen about 1 to 2 hours after you start taking PLENVU.</item>
                                 <item>
                                    <caption>•</caption>If you take too much PLENVU, call your healthcare provider.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of PLENVU?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">PLENVU can cause serious side effects including:</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Changes in certain blood tests. </content>Your healthcare provider may do blood tests after you take PLENVU to check your blood for changes. Tell your healthcare provider if you have any symptoms of too much fluid loss, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>vomiting</item>
                                 <item>
                                    <caption>•</caption>dizziness</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>heart problems</item>
                                 <item>
                                    <caption>•</caption>kidney problems</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>seizures</item>
                                 <item>
                                    <caption>•</caption>dry mouth</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td colspan="4" styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>feel faint, weak or lightheaded especially when you stand up (orthostatic hypotension)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Ulcers of the bowel or bowel problems (ischemic colitis):</content> Tell your healthcare provider right away if you have severe stomach-area (abdomen) pain or rectal bleeding.</item>
                                 <item>
                                    <caption>•</caption>
                                    <content styleCode="bold">Serious allergic reactions.</content> Symptoms of a serious allergic reaction may include:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>skin rash</item>
                                 <item>
                                    <caption>•</caption>itching</item>
                              </list>
                           </td>
                           <td colspan="2" valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>raised red patches on your skin (hives)</item>
                                 <item>
                                    <caption>•</caption>swelling of the face, lips, tongue and throat</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>kidney problems</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of PLENVU include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " valign="top"/>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>nausea</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>vomiting</item>
                              </list>
                           </td>
                           <td valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>dehydration</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>stomach pain or discomfort</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>These are not all the possible side effects of PLENVU.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">How should I store PLENVU?</content>
                              </paragraph>
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Store PLENVU (before opening and after mixed) at room temperature, between 68°F to 77°F <br/>(20°C to 25°C). PLENVU (before opening and after mixed) may also be stored in a refrigerator.</item>
                                 <item>
                                    <caption>•</caption>Use PLENVU within 24 hours after mixing with water.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep PLENVU and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of PLENVU.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use PLENVU for a condition for which it was not prescribed. Do not give PLENVU to other people, even if they are going to have the same procedure you are. It may harm them.</paragraph>
                              <paragraph>You can ask your pharmacist or healthcare provider for information that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Lrule Botrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in PLENVU?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient:</content>
                              </paragraph>
                              <paragraph>Dose 1: PEG 3350, sodium sulfate, sodium chloride, potassium chloride</paragraph>
                              <paragraph>Dose 2 Pouch A: PEG 3350, sodium chloride, potassium chloride</paragraph>
                              <paragraph>Dose 2 Pouch B: sodium ascorbate, ascorbic acid</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content>
                              </paragraph>
                              <paragraph>Dose 1: sucralose, encapsulated citric acid, mango flavoring</paragraph>
                              <paragraph>Dose 2 Pouch A: aspartame, fruit punch flavoring</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="5" styleCode="Rrule Botrule Lrule " valign="top">
                              <paragraph>
                                 <content styleCode="bold">Distributed by:</content>
                              </paragraph>
                              <paragraph>Salix Pharmaceuticals, a division of</paragraph>
                              <paragraph>Bausch Health US, LLC</paragraph>
                              <paragraph>Bridgewater, NJ 08807 USA<br/>
                                 <br/>
                                 <content styleCode="bold">Manufactured by:</content>
                              </paragraph>
                              <paragraph>Norgine Limited</paragraph>
                              <paragraph>7 Tir-y-berth Industrial Estate</paragraph>
                              <paragraph>New Road, Tir-y-berth</paragraph>
                              <paragraph>Hengoed, CF82 8SJ</paragraph>
                              <paragraph>United Kingdom (GBR)</paragraph>
                              <paragraph>Patented. See https://patents.salix.com for US patent information.</paragraph>
                              <paragraph>PLENVU is a registered trademark of the Norgine group of companies used under license.</paragraph>
                              <paragraph>© 2023 Salix Pharmaceuticals, Inc. or its affiliates</paragraph>
                              <paragraph>For more information, go to www.PLENVU.com or call 1-800-321-4576.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.                          </paragraph>
                  <list listType="ordered">
                     <item>
                        <caption> </caption>Revised: 9/2023                        	         9643003</item>
                     <item>
                        <caption> </caption>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230901"/>
            </section>
         </component>
         <component>
            <section ID="ID_72c4bbed-ffbd-4ee2-8515-579c87a29d4a">
               <id root="93490b1f-85f5-4cc7-a22c-d3835d4d1392"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions for Use </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">PLENVU<sup>® </sup>(plen-vu)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution)</content>
                  </paragraph>
                  <paragraph>There are two different options for taking PLENVU. Your healthcare provider will tell you to take the Two-Day Split-Dosage option or the One-Day Morning Dosage option.</paragraph>
                  <paragraph>
                     <content styleCode="bold">The following are provided with the pack:</content>
                  </paragraph>
                  <table width="100%">
                     <col width="25%"/>
                     <col width="25%"/>
                     <col width="26%"/>
                     <col width="23%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Botrule Toprule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>An outer carton:</item>
                              </list>
                              <renderMultiMedia ID="ID0EAPCM" referencedObject="ID_89edb3bc-f4d3-4cf2-9edf-57fcbf303ed3"/>
                           </td>
                           <td align="center" styleCode="Botrule Toprule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>An inner carton:</item>
                              </list>
                              <renderMultiMedia ID="ID0EXSCM" referencedObject="ID_0782f4af-6f69-4ff1-b94f-cc27bc9bc633"/>
                           </td>
                           <td align="center" styleCode="Botrule Toprule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>A mixing container<br/>with removable lid:</item>
                              </list>
                              <renderMultiMedia ID="ID0EQWCM" referencedObject="DBECCDDC-4222-4C96-BFFE-5808B78BC65E"/>
                           </td>
                           <td align="center" styleCode="Botrule Toprule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Prescribing Information<br/>and Patient Information</item>
                              </list>
                              <renderMultiMedia ID="ID0EJ1CM" referencedObject="ID_9b55dbb6-d155-4a2d-90a7-03612887b5ee"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">The inner carton contains:</content>
                  </paragraph>
                  <table width="100%">
                     <col width="37%"/>
                     <col width="63%"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode="Botrule Toprule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Dose 1</item>
                              </list>
                              <renderMultiMedia ID="ID0EJ6CM" referencedObject="A53E37EF-D406-4880-97D5-8DD6367F30AE"/>
                           </td>
                           <td align="center" styleCode="Botrule Toprule " valign="top">
                              <list listType="unordered">
                                 <item>
                                    <caption>•</caption>Dose 2 Pouch A and Dose 2<br/>Pouch B (to be taken together)</item>
                              </list>
                              <renderMultiMedia ID="ID0EEDDM" referencedObject="B85BE317-82A7-45DF-ADD1-E41755363FCB"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Additional supplies </content>(not included in the pack):</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Water (to mix with PLENVU).</item>
                     <item>
                        <caption>•</caption>Scissors (optional to cut the pouches on the dotted line).</item>
                     <item>
                        <caption>•</caption>Spoon (optional to mix the water and PLENVU together. You can also mix the water and PLENVU by putting the lid on securely and shaking it. See step 1c below).</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Important Information on PLENVU:</content>
                     </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>You must drink all of Dose 1 (one pouch) and Dose 2 (two pouches) of PLENVU for either dosing option. Make sure you finish Dose 2 at least 2 hours before your colonoscopy. <content styleCode="bold">Do not </content>add any other ingredients to PLENVU.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">Do no</content>t mix PLENVU with starch-based thickeners.</item>
                     <item>
                        <caption>•</caption>PLENVU <content styleCode="bold">must </content>be mixed with water.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Drink clear liquids before, during, and after you take PLENVU, up until 2 hours before your colonoscopy, to help prevent fluid loss (dehydration), and changes in blood salt (electrolyte) levels.</content>
                     </item>
                  </list>
                  <paragraph>It is important for you to drink the additional amount of clear liquids listed here in the Instructions for Use.</paragraph>
                  <paragraph>Examples of clear liquids are:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>water</item>
                           <item>
                              <caption>•</caption>clear broth soups</item>
                           <item>
                              <caption>•</caption>herbal tea, black tea or coffee</item>
                           <item>
                              <caption>•</caption>watered down (diluted) (from concentrate) clear fruit juices (without pulp) including apple juice or white grape juice</item>
                           <item>
                              <caption>•</caption>clear soda</item>
                           <item>
                              <caption>•</caption>gelatin (without added fruit or topping)</item>
                           <item>
                              <caption>•</caption>popsicles (without pieces of fruit or fruit pulp)</item>
                           <item>
                              <caption>•</caption>strained limeade or lemonade</item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Do not </content>eat or drink alcohol, milk, anything colored red or purple or any foods that have pulp.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Do not </content>take other laxatives while taking PLENVU.</item>
                     <item>
                        <caption>•</caption>If you need to take any other medicines by mouth (oral), take those medicines at least 1 hour before starting each dose of PLENVU.</item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Do not </content>eat solid food while taking PLENVU until after your colonoscopy.</item>
                     <item>
                        <caption>•</caption>For the Two-Day Split Dosage schedule:<list listType="unordered">
                           <item>
                              <caption>•</caption>On the day before the colonoscopy you can eat a light breakfast followed by a light lunch.</item>
                           <item>
                              <caption>•</caption>You must finish eating lunch at least 3 hours before you start taking PLENVU.</item>
                           <item>
                              <caption>•</caption>After you start taking PLENVU you can only drink clear liquids.</item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>For the One-Day Morning Dosage schedule:<list listType="unordered">
                           <item>
                              <caption>•</caption>On the day before the colonoscopy you can eat a light breakfast followed by a light lunch. For dinner you may have clear broth soup or plain yogurt.</item>
                           <item>
                              <caption>•</caption>You should finish dinner by about 8 pm.</item>
                           <item>
                              <caption>•</caption>After you start taking PLENVU you can only drink clear liquids.</item>
                        </list>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="bold">Do not </content>eat the morning of your colonoscopy.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">Two-Day Split Dosage Schedule</content>
                     </content>
                  </paragraph>
                  <paragraph>Take Dose 1 in the evening sometime between 4 pm and 8 pm.</paragraph>
                  <paragraph>Take Dose 2 the next morning, on the day of the colonoscopy. This should be about 12 hours (between about 4 am and 8 am) after you started Dose 1. Make sure you finish Dose 2 at least 2 hours before your colonoscopy.</paragraph>
                  <paragraph>Follow Step 1 to Step 3 on how to mix with a spoon or shake with lid on securely and take PLENVU:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 1a: </content>Empty Dose 1 into the mixing container that comes with your PLENVU.</item>
                  </list>
                  <renderMultiMedia ID="ID0EHDEM" referencedObject="ID_61eb841b-3a8e-402e-9ae7-ca3c6be54263"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 1b: </content>Add water to the fill line. You will need to add at least 16 ounces.</item>
                  </list>
                  <renderMultiMedia ID="ID0EPGEM" referencedObject="ID_87fe41ee-f771-439a-8b32-13f2030668a2"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 1c: </content>Mix the water and PLENVU together with a spoon or put lid on mixing container securely and shake the water and PLENVU, until it is completely dissolved. This can take 2 to 3 minutes.</item>
                  </list>
                  <renderMultiMedia ID="ID0EXJEM" referencedObject="DB701151-36E5-4456-BD44-1731D80A98F3"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 2: </content>Drink the entire contents of the mixing container over the next 30 minutes. </item>
                     <item>
                        <caption> </caption>If you feel like you have severe stomach pain or discomfort you can stop taking PLENVU for a short time and then continue taking it or you can take smaller sips of PLENVU so that you space out your dose longer than 30 minutes. If you still have severe stomach pain, call your healthcare provider.</item>
                  </list>
                  <renderMultiMedia ID="ID0ESNEM" referencedObject="DBD46C8C-61E9-4CFE-9B76-0697B4FF6481"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 3: </content>Rinse the mixing container with water. Refill to the fill line with clear liquids. This will be at least 16 ounces. Drink the entire contents of the mixing container over the next 30 minutes. <content styleCode="bold">Continue to drink additional clear liquids during the evening as this is important to help avoid dehydration. </content>For a list of clear liquids, see examples at the top of the Instructions for Use.</item>
                  </list>
                  <renderMultiMedia ID="ID0E5QEM" referencedObject="ID_359de53e-0941-42bb-84b0-06e92dc4b586"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>After taking PLENVU if you have any bloating or feeling like your stomach is upset, wait to take Dose 2 until your stomach feels better.<br/>
                        <br/>
                        <content styleCode="bold">For Dose 2: </content>Rinse the mixing container with water. Repeat Steps 1, 2 and 3 but this time for Dose 2 you will empty two dose pouches (Dose 2 Pouch A and Dose 2 Pouch B) into the mixing container at the same time. <br/>
                        <br/>After drinking your 16 ounces of water mixed with PLENVU and the 16 ounces of the clear liquids, <content styleCode="bold">it is important that you drink additional clear liquids to help avoid dehydration</content>. For a list of clear liquids, see examples at the top of the Instructions for Use. <content styleCode="bold">You must stop drinking all liquids at least 2 hours before your colonoscopy.</content>
                     </item>
                  </list>
                  <renderMultiMedia ID="ID0ESVEM" referencedObject="ID_570a374e-663e-432e-89fc-ec639b74d073"/>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="underline">One-Day Morning Dosage Schedule</content>
                     </content>
                  </paragraph>
                  <paragraph>Take Dose 1 the morning of your colonoscopy sometime between 3 am and 7 am.</paragraph>
                  <paragraph>Take Dose 2 about two hours after you start Dose 1. Make sure you finish Dose 2 at least 2 hours before your colonoscopy.</paragraph>
                  <paragraph>Follow Step 1, Step 2 and Step 3 on how to mix with a spoon or shake with lid on securely and take PLENVU:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 1a: </content>Empty Dose 1 into the mixing container that comes with your PLENVU.</item>
                  </list>
                  <renderMultiMedia ID="ID0EE2EM" referencedObject="ID_17d70335-905a-45dd-a608-31fd485090f9"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 1b: </content>Add water to the fill line. You will need to add at least 16 ounces.</item>
                  </list>
                  <renderMultiMedia ID="ID0EM5EM" referencedObject="F23E7BC9-2F0E-481F-9FCB-065F5BF096C0"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 1c: </content>Mix the water and PLENVU together with a spoon or put lid on mixing container securely and shake the water and PLENVU, until it is completely dissolved. This can take 2 to 3 minutes.</item>
                  </list>
                  <renderMultiMedia ID="ID0EVBFM" referencedObject="ID_50908591-3bdb-4770-b02a-7cdc361fca29"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 2: </content>Drink the entire contents of the mixing container over the next 30 minutes.</item>
                     <item>
                        <caption> </caption>If you feel like you have severe stomach pain or discomfort you can stop taking PLENVU for a short time and then continue taking it or you can take smaller sips of PLENVU so that you space out your dose longer than 30 minutes. If you still have severe stomach pain, call your healthcare provider.</item>
                  </list>
                  <renderMultiMedia ID="ID0EQFFM" referencedObject="ID_85163df0-1223-471f-a265-002e2543ca0d"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>
                        <content styleCode="bold">Step 3: </content>Rinse the mixing container with water. Refill to fill line with clear liquids. This will be at least 16 ounces. Drink the entire contents of the mixing container over the next 30 minutes. <br/>
                        <br/>After drinking your 16 ounces of water mixed with PLENVU and the 16 ounces of the clear liquids, it is <content styleCode="bold">important</content> that you drink additional clear liquids <content styleCode="bold">in the morning before Dose 2</content> to help avoid dehydration. For a list of clear liquids, see examples at the top of the Instructions for Use. <content styleCode="bold">You must stop drinking all liquids at least 2 hours before your colonoscopy. </content>
                     </item>
                  </list>
                  <renderMultiMedia ID="ID0EVJFM" referencedObject="ID_1794d2b8-377b-42d6-a381-4c788d37cbbf"/>
                  <list listType="unordered">
                     <item>
                        <caption> </caption>After taking PLENVU if you have any bloating or feeling like your stomach is upset, wait to take Dose 2 until your stomach feels better.<br/>
                        <br/>
                        <content styleCode="bold">For Dose 2: </content>Rinse the mixing container with water. Repeat Step 1, Step 2 and Step 3 but this time for Dose 2 you will empty two dose pouches (Dose 2 Pouch A and Dose 2 Pouch B) into the mixing container at the same time. <br/>
                        <br/>
                        <content styleCode="bold">After drinking your 16 ounces of water mixed with PLENVU and the 16 ounces of the clear liquids, it is important that you drink additional clear liquids to help avoid dehydration. </content>For a list of clear liquids, see examples at the top of the Instructions for Use.<content styleCode="bold"> You must stop drinking all liquids at least 2 hours before your colonoscopy. </content>
                     </item>
                  </list>
                  <renderMultiMedia ID="ID0ELOFM" referencedObject="C7AF4307-AD82-4028-BF1F-98E4E1301E23"/>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                     <br/>Salix Pharmaceuticals, a division of<br/>Bausch Health US, LLC<br/>Bridgewater, NJ 08807 USA</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                     <br/>Norgine Limited<br/>7 Tir-y-berth Industrial Estate<br/>New Road, Tir-y-berth<br/>Hengoed, CF82 8SJ<br/>United Kingdom (GBR)</paragraph>
                  <paragraph>Patented. See https://patents.salix.com for US patent information.</paragraph>
                  <paragraph>PLENVU is a registered trademark of the Norgine group of companies used under license.<br/>© 2023 Salix Pharmaceuticals, Inc. or its affiliates<br/>This Instructions for Use has been approved by the U.S. Food and Drug Administration.<br/>Revised: 9/2023</paragraph>
                  <paragraph>9643003</paragraph>
               </text>
               <effectiveTime value="20230901"/>
               <component>
                  <observationMedia ID="ID_89edb3bc-f4d3-4cf2-9edf-57fcbf303ed3">
                     <text>outer carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_0782f4af-6f69-4ff1-b94f-cc27bc9bc633">
                     <text>inner carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DBECCDDC-4222-4C96-BFFE-5808B78BC65E">
                     <text>mixing container</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_9b55dbb6-d155-4a2d-90a7-03612887b5ee">
                     <text>PI and PPI</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="A53E37EF-D406-4880-97D5-8DD6367F30AE">
                     <text>Dose 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="B85BE317-82A7-45DF-ADD1-E41755363FCB">
                     <text>Dose 2 A and B</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_61eb841b-3a8e-402e-9ae7-ca3c6be54263">
                     <text>Step 1a</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_87fe41ee-f771-439a-8b32-13f2030668a2">
                     <text>Step 1b</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DB701151-36E5-4456-BD44-1731D80A98F3">
                     <text>Step 1c</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="DBD46C8C-61E9-4CFE-9B76-0697B4FF6481">
                     <text>Step 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_359de53e-0941-42bb-84b0-06e92dc4b586">
                     <text>Step 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_570a374e-663e-432e-89fc-ec639b74d073">
                     <text>Dose 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_17d70335-905a-45dd-a608-31fd485090f9">
                     <text>One Day Step 1a</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="F23E7BC9-2F0E-481F-9FCB-065F5BF096C0">
                     <text>One Day Step 1b</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_50908591-3bdb-4770-b02a-7cdc361fca29">
                     <text>One Day Step 1c</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_85163df0-1223-471f-a265-002e2543ca0d">
                     <text>One Day Step 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_1794d2b8-377b-42d6-a381-4c788d37cbbf">
                     <text>One Day Step 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="C7AF4307-AD82-4028-BF1F-98E4E1301E23">
                     <text>One Day Dose 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="3bbbfd09-4f0b-4d76-ab63-240307c8098d-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_22f06176-f2a6-4654-b85c-f81df7900ea5">
               <id root="2afea1f8-e0e2-4518-b51a-993b1757aab9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – Plenvu Outer Carton</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                     <br/>
                     <content styleCode="bold">NDC </content>65649-400-01<br/>PLENVU<sup>®</sup>
                  </paragraph>
                  <paragraph>(polyethylene glycol 3350, sodium ascorbate, <br/>sodium sulfate, ascorbic acid, sodium chloride<br/>and potassium chloride for oral solution)<br/>140 g, 48.11 g, 9 g, 7.54 g, 5.2 g, 2.2 g</paragraph>
                  <paragraph>This carton contains:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Dose 1</item>
                     <item>
                        <caption>•</caption>Dose 2 Pouch A<br/>and Dose 2 Pouch B</item>
                     <item>
                        <caption>•</caption>Mixing container with<br/>fill line</item>
                     <item>
                        <caption>•</caption>Prescribing Information<br/>and patient information</item>
                  </list>
                  <paragraph>Dose 1 Pouch contains<br/>115.96 g of powder for<br/>oral solution.</paragraph>
                  <paragraph>Dose 2 Pouch A contains<br/>46.26 g of powder for <br/>oral solution.</paragraph>
                  <paragraph>Dose 2 Pouch B contains<br/>55.65 g of powder for <br/>oral solution.</paragraph>
                  <paragraph>
                     <content styleCode="bold">All of Dose 1 (one pouch) and Dose 2</content>
                     <br/>
                     <content styleCode="bold">(two pouches) must be consumed.</content>
                  </paragraph>
                  <paragraph>Follow the instructions provided prior <br/>to use.</paragraph>
                  <paragraph>Phenylketonurics: Contains Phenylalanine<br/>491 mg per treatment.</paragraph>
                  <paragraph>Dispense the enclosed Medication Guide<br/>to each patient.</paragraph>
                  <paragraph>Reconstitute and dilute in water prior<br/>to use.</paragraph>
                  <paragraph>Salix <br/>PHARMACEUTICALS</paragraph>
                  <paragraph>9642903 </paragraph>
                  <renderMultiMedia ID="id1289085776" referencedObject="ID_7110fa5e-bf02-4d0a-a8e4-920028cf080a"/>
               </text>
               <effectiveTime value="20230901"/>
               <component>
                  <observationMedia ID="ID_7110fa5e-bf02-4d0a-a8e4-920028cf080a">
                     <text>Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="image-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>